NFE2L2 and non-small cell lung carcinoma: Activation of both Nrf2 and the KEAP1/Nrf2 pathway increases glutamine metabolism and promotes cell survival in KRAS-mutated pancreatic and non-small cell lung cancers, leading to greater chemoresistance [85,86].